Every 10-Q that Pfizer Inc. (PFE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
Pfizer Inc. reported Q2 2026 revenues of $15,034 million, slightly above $14,653 million a year earlier, but swung to a net loss attributable to common shareholders of $(248) million, or $(0.04) per basic and diluted share, versus earnings of $0.51. Results were heavily affected by $4,325 million of intangible asset impairments, mainly $3,800 million for an IPR&D asset (sigvotatug vedotin) after unfavorable Phase 3 results and $525 million for Oxbryta developed technology rights, partially offset by a $1,870 million gain on sale of the ViiV stake.
For the first six months of 2026, revenues were $29,484 million and net income attributable to common shareholders was $2,440 million, or $0.43 per share, compared with $28,367 million and $5,877 million in 2025. Operating cash flow improved to $3,450 million. Long-term debt was $60,495 million and total equity $85,492 million at June 28, 2026.
Pfizer highlighted strategic actions including the $8.0 billion Metsera acquisition, adding $7.9 billion of IPR&D and $2.1 billion of goodwill, the completion of its exit from ViiV for $1,875 million in cash, a Sciwind ecnoglutide in-licensing deal with up to $495 million in potential milestones, and large multi-year cost realignment and manufacturing optimization programs with expected aggregate one-time costs of $12.7 billion and cumulative spending to date of $4.9 billion and $1.1 billion, respectively.
Pfizer Inc. reported first‑quarter 2026 results showing modest growth in sales but lower earnings. Total revenues were $14,451 million, up from $13,715 million a year earlier, driven by higher product, alliance and royalty revenues.
Income from continuing operations was $2,709 million versus $2,973 million, and diluted EPS was $0.47 compared with $0.52. Operating cash flow was $2,615 million, and cash and cash equivalents rose to $1,703 million. At April 29, 2026, 5,699,444,169 common shares were outstanding.
The balance sheet showed total assets of $207,618 million and long‑term debt of $60,565 million. Pfizer highlighted its $8.0 billion Metsera acquisition, ongoing multi‑year cost‑reduction and manufacturing optimization programs, and restructuring and acquisition‑related costs of $195 million in the quarter.
Pfizer Inc. filed its Q3 2025 report, showing lower quarterly results versus last year and executing major portfolio moves. Total revenues were $16,654 million, down from $17,702 million in Q3 2024, and diluted EPS was $0.62 versus $0.78. Year-to-date, net income attributable to common shareholders was $9,419 million, up from $7,621 million, aided by a negative effective tax rate and portfolio actions.
The company recorded a $1,350 million charge in Acquired in-process R&D tied to an exclusive global (ex-China) in-licensing of SSGJ-707 from 3SBio, which also included a $100 million equity investment and up to $4,800 million in potential milestones. Pfizer also entered R&D funding arrangements with Abingworth (up to $200 million through 2027) and Blackstone (up to $326 million through 2028), with approval- and sales-based milestone payment structures after potential approvals.
Pfizer continued multi-year cost programs: the Realigning Our Cost Base Program and the Manufacturing Optimization Program. Cumulative costs through September 28, 2025 reached $3.7 billion for the realignment and $1.0 billion for manufacturing optimization. Cash from investing included $6,311 million of proceeds from sales of the remaining Haleon stake. Shares outstanding were 5,685,707,552 as of October 29, 2025.